Treatment of Chronic Hepatitis with Sofosbuvir in Combination with Ribavirin with or without Pegylated Interferon

Abstract

Introduction: We performed an retrospective analysis to determine the efficacy and safety of sofosbuvir plus ribavirin, with and without peginterferon-alfa, in treatment naive and experienced patients with chronic hepatitis C (CHC) genotype1 and 3 infection, with or without compensated cirrhosis.Table 1: Patient Demographic and Baseline CharacteristicsMethods: The study was conducted at 11 sites in northern India between March 2015 and Dec 2015 (n=1212). Patients with chronic hepatitis C / cirrhosis genotype 1 were treated with peginterferon-alfa 2a 180 mcg, sofosbuvir plus weight based ribavirin x 12 weeks. Patients with chronic hepatitis C genotype 3 were treated with sofosbuvir plus weight based ribavirin x 24 weeks; with cirrhosis were given peginterferon-alfa 2a 180 mcg, sofosbuvir plus weight based ribavirin x 12 weeks. The primary endpoint was the percentage of patients with HCV RNA Results: Results are given in Table 2. The most common adverse events were fatigue, headache, insomnia, and nausea. Overall 1% of patients discontinued treatment due to adverse events.Table 2: Treatment ResponseConclusion: This is the largest real life experience on treatment of CHC patients globally. SVR rates in CHC patients of genotypes 1 and 3 treated in India were as high as in western population.